Cefpodoxime Proxetil EP Impurity E

Stability indicating HPLC method development and validation for the simultaneous determination of Cefpodoxime Proxetil and Ofloxacin in its dosage forms
By Ghode, Prashant D.; Pawar, Sunil P.
From International Journal of Pharma and Bio Sciences (2015), 6(2), 183-193
 
Stability indicating method development degradation studies and validation of cefpodoxime proxetil by RP-​HPLC method
By Kamalesh, G.; Madhuri, D.; Nagarajan, G.
From International Journal for Pharmaceutical Research Scholars (2014), 3(4), 269-275, 7 pp..
 
Characterization of impurities in cefpodoxime proxetil using LC-​MS (n)
By Li Jin; Zhang Dousheng; Hu Changqin
From Acta pharmaceutica Sinica. B (2014), 4(4), 322-32

Cefpodoxime Proxetil EP Impurity E is chemically (1RS)-1-[[(1-Methylethoxy)carbonyl]oxy]ethyl (6R,7R)-3-(acetoxymethyl)-7-[[(2Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate (as per EP). It is also known as ACA-Analogue of Cefpodoxime Proxetil. Cefpodoxime Proxetil EP Impurity E is supplied with detailed characterization data compliant with regulatory guideline. Cefpodoxime Proxetil EP Impurity E can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Cefpodoxime Proxetil.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.